PDA和全球制藥工業(yè)(Robert-Dana)課件_第1頁
PDA和全球制藥工業(yè)(Robert-Dana)課件_第2頁
PDA和全球制藥工業(yè)(Robert-Dana)課件_第3頁
PDA和全球制藥工業(yè)(Robert-Dana)課件_第4頁
PDA和全球制藥工業(yè)(Robert-Dana)課件_第5頁
已閱讀5頁,還剩45頁未讀, 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡介

PDA

ConnectingPeople,ScienceandRegulation?PDAandtheGlobalPharmaceuticalMarketPresentedatthe2011ParenteralDrugIndustryCongress,Beijing,ChinaSeptember2011PDAandtheGlobalPharmaceuticalMarketAboutPDATheGlobalPharmaceuticalMarketSummary4AgendaAboutPDAWhoarewe?OurVision,Mission&FocusOurActivitiesMemberCoreCompetenciesMemberBenefits5Weare:

Acommunityof9,500individualmemberscientistsandprofessionalsin70countriesrepresentinglargeandsmallpharmaceuticalandbiopharmaceuticalcompanies,regulatoryagencies,suppliersandacademia.6OurVision

Tobetheforemostglobalproviderofscience,technology,andregulatoryinformationandeducationforthepharmaceuticalandbiopharmaceuticalcommunity.7OurMissionTodevelopscientificallysound,practicaltechnicalinformationandresourcestoadvancescienceandregulationforthepharmaceuticalandbiopharmaceuticalindustrythroughtheexpertiseofourglobalmembership.8StrategicFocus

9OurActivities(Volunteers)Over1,000PDAvolunteersworldwideactivelycarryoutitsmission.PDAisaninfluentialvoiceandaleadingtechnicalorganizationinthefieldofpharmaceuticalscienceandtechnology.ThroughthedevelopmentofTechnicalReportsandresponsestoregulatoryinitiatives,PDAanditsmembersinfluencethefuturecourseofpharmaceutical/biopharmaceuticalproductstechnology.910IntheareasofScienceandTechnology,PDAinfluencesindustrydirection

DevelopspositionsoncurrentandproposedapplicationsoftechnologyRootedinscienceConsensusdrivenRepresentindustrybestpracticesIdentifiesandmonitorsnewtechnologiesOurActivities(SciTech)11SupportstheapplicationoftechnologyandcompliancerequirementsthroughmembershipparticipationScienceAdvisoryBoard(SAB)BiotechnologyAdvisoryBoard(BioAB)RegulatoryAffairsandQualityAdvisoryBoard(RAQAB)InterestGroups(IGs)TaskForces(TFs)OurActivities(SciTech)Cont.12PDAInterestGroupsarealignedtoAdvisoryBoardsInterestGroupsBIOABSABRAQABBiotechnologyBlowFillSealClinicalTrialMaterialsCombinationProductsFacilitiesandEngineeringInspectionTrendsLyophilizationFiltrationQualityRiskManagementPharmaceuticalColdChainMicrobiology/EMQualitySystemsVaccinesPackagingScienceRegulatoryAffairsPharmaceuticalWaterSystemsPrefilledSyringesProcessValidationSterileProcessingSupplyChainManagementTechnologyTransferVisualInspection1213OurActivities(TRs)TechnicalReportsMeantasrecommendation,andguidance,butarenon-prescriptive

However:MostreadanduseddocumentsbyregulatorsandindustryTRshaveinfluencedregulatoryGuidances,e.g.FDA’s2004AsepticGuideline,ISO13408-2andPIC/SAsepticGuide.NewTechnicalReports(2010and2011YeartoDate)TR47-PreparationofVirusSpikesUsedforVirusClearanceStudiesTR48-MoistHeatSterilizerSystems:Design,Commissioning,Operation,QualificationandMaintenanceTR49-PointstoConsiderforBiotechnologyCleaningValidationTR50-AlternativeMethodsforMycoplasmaTestingTR51-BiologicalIndicatorsforGasandVapor-PhaseDecontaminationProcesses:Specification,Manufacture,ControlandUseTR52-GuidanceforGoodDistributionPracticesforthePharmaceuticalSupplyChainTR53–GuidanceforIndustry:StabilityTestingtoSupportDistributionofNewDrugProducts15OurActivities

(Regulations)MonitorGlobalRegulatoryActivityPrimaryFocus:U.S.andEuropeanRegulatoryAgenciesIncludesICH,PIC/S,USP,EPandWHODevelopinginterestinAsiaandIndia

InfluenceGlobalRegulatoryPolicyInteractionswithglobalregulatoryauthoritiesCo-sponsormeetingswithRegulators(FDA,EMA,PIC/S,ICH)CommentsonproposedregulationsandguidancePromotescience-basedregulationsOurActivities(PCMOSM)16Scope UtilizingPDA’smembershipexpertisetodrive:theestablishmentof“bestpractice”documentstrainingeventsandcoursestoaidthepharmaceuticalmanufacturers’toimplementICHQ8,Q9andQ10IMPandcommercialproductsSeeourprojectdossieronthePDAwebsite(/pcmo)

formoreinformation17OurActivities(PCMOSM)Objectives

EnableaninnovativeenvironmentforcontinualimprovementofproductsandsystemsPutscienceintopracticeEnableincreaseofprocessrobustnessandknowledgeFosterrelieffromregulatoryprescriptionsPCMOProjectsLifecycleIMPmanufactureanddistributionImplementationofQbDinManufacturingTechnologyTransferSupplyChain/GoodDistributionPracticesQualitySystemsCapturingknowledgemanagementduringcommercialmanufacturingManagementofSuppliersandContractorsEstablishingaPharmaceuticalQualitySystemConceptsfortrainingAdditionalPCMOProjectsProcessFromProcessValidationtoProcessVerificationConceptsforCleaningValidationHowtoimproverobustnessofamanufacturingprocessUtilizationofstatisticalmethodsforproductionandbusinessprocessesCorrectiveandpreventiveactionsRiskManagementRiskBasedManufacturingSterileAPIsRisk-Basedschedulingofaudits20OurActivities(Conferences)World-classevents

Designedto

EducatePromoteinteractionAdvancememberinterestsGlobalvenuesScienceandRegulatoryfocus21OurActivities(TRI)State-of-the-arttrainingfacilityLearninginariskfreeenvironmentPDATraining&ResearchInstitute22TheTRICurriculum

ValidationLyophilizationPre-filledSyringesSterilizationTechnologyColdChainVisualInspectionAsepticProcessingBiotechnologyEnvironmentalMonitoringFiltrationMicrobiologyQuality/RegulatoryAffairsIncludescoursesin:23PDA’sStateoftheArtTrainingFacilityandRemoteCoursesBringConsistencyWorldwidePDAhasprovidedInspectorate

Trainingtoanumberofcountries Themostrecentare:RussiaKazakhstanEMAandmanyoftheEUInspectorate-Italy,UK,Ireland,Sweden,etc.USFDATraininghasbeenconductedinRussianandChineselanguagesOurActivities(Membership)MembershipcompetenciesMembershipbenefitsNewmembershipcategoryforemergingeconomies2425MembershipCoreCompetenciesAppliedSciencesAsepticProcessingManufacturingProcessEngineeringBiotechnologyMicrobiologyProcessValidation25QualityandRegulatoryRegulatory Compliance/GMPSupplyChainQualitySystems26MembershipBenefitsProfessionalResources&NetworkInterestGroupsTaskForcesChaptersCareerServiceCenterStudentScientificProgramsSci-TechDiscussionGroupOnlineMembershipDirectory27PublicationsPDAJournalofPharmaceuticalScience&TechnologyPDALetterTechnicalReportsBooksandScientificPublicationsMembershipBenefits(Cont.)28PDAJournalWebsiteJournalHighWirewebsitelaunchedin2009EasytouseandsearchArchivesbackto1998MorefeaturestocomeNewJournalEditorialStaffonboardRenewedemphasisoncorePDAmemberinterestsBiotech,Microbiology,AsepticProcessingandManufacturingarticlesdesiredNewReducedCostMembershipForemergingeconomies(includingChina)Electronicaccessto:PDAJournalwebsite,currentandprioryearPDALetterPDAmembershipdirectoryNoaccessto:ElectronicTechnicalReportsPrintversionofPDALetterAnnualCost:$100.00[canupgradetofullmembershipforadditional$149.00(total$249)]30SummaryPDAoffersauniquenetworkandplatformtoexchangeknowledgeandexperiencesPDAhasstrongrelationshipswithglobalregulatorsandstandardsettingorganizationsanditsTechnicalReportsarewelcomedPDAservestheindustrywithbyinfluencingscientific,technological®ulatorytrendsPDAistheorganizationforparenteralsTheGlobalPharmaceuticalMarketAgendaBusinessEnvironmentPharmaManufacturingEnvironmentRegulatoryEnvironmentClosingThoughts32BusinessChangesinPharmaDependenceonBlockbustersEmergingMarketsLossofPatentProtectionConsolidation/Mergers&Acquisitions33DependenceonBlockbusters34DiversificationviaGeographicExpansion

Emergingmarkets–shareofglobalpharmagrowth:

Source;IMSHealth35Patent“Cliff”36RecentPharmaMergersandAcquisitions37Processeshavebeenevolving…Frommortarandpestletohighlycomplexbioreactors.Frommanuallyintensiveasepticprocessestohighlyautomatedequipmentwithadvancedenvironmentalcontrols.FromtesttubestoRamanspectroscopy.FromPenandPapertoGigabytesofelectronicdata.38ThePharmaceuticalSupplyChainhasbecomemorecomplexGlobalizationofSupplyChainMoreoff-shoresourcinganddistributionIncreasedpercentageof“coldchain”productsIncreaseindiversion,counterfeitingand“economicallymotivatedadulteration”39Ourconceptofqualityhaschanged…FromtestandreleasetoQualityAssurancetoQualitybyDesign.From‘craftmanship’tovalidatedprocesses.FromR&D/Manufacturing/QualitysilostoQualitySystemApproachthatreachesfrombeginningofnewproductsthroughoutthelifecycle.40Ourregulatoryframeworkhasalsochanged…30yearsago:Highlyfragmented,lackofconsistency,20yearsago:BeginningsofEUintegrationandinternationalharmonization.TodayAdvancesinInternationalHarmonizationTomorrowGreatercooperationandexchangeofinformationamongglobalregulators41ChallengesforthePharmaceuticalIndustryinthe21stCenturyGlobalizationRationalizationIntegrationCostReductionSupplyChainIntegrityAlladduptoincreasedComplexity42GlobalizationRationalizationofManufacturingcapacityisoccurringatthesametimethatglobaldemandforpharmaceuticalsisrising.Growthrateismostnoticeablein“pharmerging”marketsChina,Brazil,Mexico,SouthKorea,India,TurkeyandRussiavs.US/EU/JapanCostpressuresaredrivingmoremanufacturingto“pharmerging”countries43RationalizationPharmamanufacturinghasover-capacityReductionoffacilitiesisongoingImpactisgreatestinUSandEuropeProductrationalizationisongoingatmajorpharma44IntegrationIntegratingmergerpartnersIntegratingCROsandCMOsIntegratingSuppliersAPIsExcipientsPackagingComponentsKeyManufacturingmaterials45CostReductionDeclineintop-linerevenueaddspressureonPharmacompaniestoreduceexpensestomaintainbottomlinerevenueRationalizationofovercapacityPricingpressureonmaterialsandCostofGoodsGovernmentpricingpressureisincreasingworldwide46SupplyChainIntegrityEnhancingSupplierQualityManagementsupplierselectionandqualificationprocesses,on-goingmonitoringandmanagement.IncreasingSupplyChainControlsforincomingmaterialsandcomp

溫馨提示

  • 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

最新文檔

評論

0/150

提交評論